Tumor necrosis factor receptor
From Proteopedia
(Difference between revisions)
| Line 65: | Line 65: | ||
**[[1aly]] – hTNFSF-5 extracellular domain <BR /> | **[[1aly]] – hTNFSF-5 extracellular domain <BR /> | ||
| - | **[[1i9r]] – hTNFSF-5 extracellular domain + antibody<BR /> | + | **[[1i9r]], [[5dmi]], [[5dmj]], [[5ihl]] – hTNFSF-5 extracellular domain + antibody<BR /> |
**[[3lkj]] – hTNFSF-5 extracellular domain + inhibitor<BR /> | **[[3lkj]] – hTNFSF-5 extracellular domain + inhibitor<BR /> | ||
**[[3qd6]] – hTNFRSF-5 extracellular domain + CD40 ligand<br /> | **[[3qd6]] – hTNFRSF-5 extracellular domain + CD40 ligand<br /> | ||
| Line 80: | Line 80: | ||
**[[4msv]] – hTNFRSF-6B extracellular domain + hTNFRSF-6 extracellular domain<br /> | **[[4msv]] – hTNFRSF-6B extracellular domain + hTNFRSF-6 extracellular domain<br /> | ||
**[[4kgg]], [[4kgq]], [[4j6g]] – hTNFRSF-6B extracellular domain + hTNFRSF-14 extracellular domain<br /> | **[[4kgg]], [[4kgq]], [[4j6g]] – hTNFRSF-6B extracellular domain + hTNFRSF-14 extracellular domain<br /> | ||
| - | **[[3mi8]] – hTNFRSF-6B extracellular domain + hTNFRSF-15 extracellular domain<br /> | + | **[[3mi8]], [[3k51]] – hTNFRSF-6B extracellular domain + hTNFRSF-15 extracellular domain<br /> |
| - | **[[ | + | **[[5l36]] – hTNFRSF-6B extracellular domain + hTNF ligand SF-6 extracellular domain<br /> |
| + | |||
| + | *Tumor necrosis factor receptor superfamily-9 (4-1BBL) | ||
| + | |||
| + | **[[2x29]] – hTNFSF-9 extracellular domain (mutant)<BR /> | ||
*Tumor necrosis factor receptor superfamily-10B (Dr5) | *Tumor necrosis factor receptor superfamily-10B (Dr5) | ||
| - | **[[2h9g]], [[4od2]], [[1za3]] – hTNFRSF-10B extracellular domain + antibody<br /> | + | **[[2h9g]], [[4od2]], [[1za3]], [[3x3f]] – hTNFRSF-10B extracellular domain + antibody<br /> |
**[[1d0g]] – hTNFRSF-10B extracellular domain + apoptosis-2 ligand<br /> | **[[1d0g]] – hTNFRSF-10B extracellular domain + apoptosis-2 ligand<br /> | ||
**[[1d4v]] – hTNFRSF-10B extracellular domain + TNF-related apoptosis inducing ligand<br /> | **[[1d4v]] – hTNFRSF-10B extracellular domain + TNF-related apoptosis inducing ligand<br /> | ||
**[[4i9x]] – hTNFRSF-10B extracellular domain + UL141<br /> | **[[4i9x]] – hTNFRSF-10B extracellular domain + UL141<br /> | ||
**[[4n90]] – hTNFRSF-10B + hTNFRSF-10 + antibody <br /> | **[[4n90]] – hTNFRSF-10B + hTNFRSF-10 + antibody <br /> | ||
| - | |||
| - | *Tumor necrosis factor receptor superfamily-9 (4-1BBL) | ||
| - | |||
| - | **[[2x29]] – hTNFSF-9 extracellular domain (mutant)<BR /> | ||
*Tumor necrosis factor receptor superfamily-11 (RANKL) | *Tumor necrosis factor receptor superfamily-11 (RANKL) | ||
| Line 105: | Line 105: | ||
**[[3me4]] – mTNFRSF-11A extracellular domain <br /> | **[[3me4]] – mTNFRSF-11A extracellular domain <br /> | ||
| + | **[[5bnq]] – mTNFRSF-11A extracellular domain + TNF ligand SF-11<br /> | ||
*Tumor necrosis factor receptor superfamily-11B (Osteoprotegerin) | *Tumor necrosis factor receptor superfamily-11B (Osteoprotegerin) | ||
| Line 152: | Line 153: | ||
**[[4f42]], [[4f44]] – hTNFRSF-16 death domain<br /> | **[[4f42]], [[4f44]] – hTNFRSF-16 death domain<br /> | ||
| + | **[[2n97]] – hTNFRSF-16 death domain - NMR<br /> | ||
**[[1sg1]], [[3ij2]] – hTNFRSF-16 + beta nerve growth factor<br /> | **[[1sg1]], [[3ij2]] – hTNFRSF-16 + beta nerve growth factor<br /> | ||
**[[3buk]] – hTNFRSF-16 + neurotrophin-3<br /> | **[[3buk]] – hTNFRSF-16 + neurotrophin-3<br /> | ||
| + | **[[2n80]] – hTNFRSF-16 death domain + rho GDP-dissociation inhibitor - NMR<br /> | ||
| + | **[[2n83]] – hTNFRSF-16 death domain + receptor interacting Ser/Thr protein kinase - NMR<br /> | ||
*Tumor necrosis factor receptor superfamily-17 | *Tumor necrosis factor receptor superfamily-17 | ||
Revision as of 10:15, 28 September 2016
| |||||||||||
3D structures of tumor necrosis factor receptor
Updated on 28-September-2016
References
- ↑ Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV, Kovalenko AV, Boldin MP. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-67. PMID:10358762 doi:http://dx.doi.org/10.1146/annurev.immunol.17.1.331
- ↑ Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L. Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol. 2015 Apr;34(4):807-9. doi: 10.1007/s10067-014-2556-8. Epub 2014, Mar 11. PMID:24609716 doi:http://dx.doi.org/10.1007/s10067-014-2556-8
- ↑ Naismith JH, Devine TQ, Kohno T, Sprang SR. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure. 1996 Nov 15;4(11):1251-62. PMID:8939750
